Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients
Panelists note how they always discuss the pro and cons of each treatment with their patients and the treatment efficiency’s, highlighting the most common and dangerous adverse effects. Panelists discuss the importance of closely monitoring patients and providing ongoing supportive care.
EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy
EP: 2.Role of Step-Up Dosing
EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy
EP: 4.Strategies For Management of Infections
Now Viewing
EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients
EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy
EP: 7.Patient Tolerability of Talquetamab and Use of IVIG
EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy
EP: 9.Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific
EP: 10.Dosing Strategies in Different Targets Bispecifics
EP: 11.Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel
Video content above is prompted by the following:
- Given this patient’s advanced age and multiple comorbidities, how would you prioritize her treatment goals (eg, efficacy vs quality of life)?
- How do you assess the risks and benefits of continuing vs switching therapies in older patients with multiple comorbidities?
- What role does supportive care play in managing chronic symptoms, and how can it be integrated into the overall treatment plan?
Recent Videos
Related Content
